Kyoto University-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kyoto University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014352
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kyoto University (Kyoto) is a research university that offers educational services. The university provides multi disciplinary courses to students of Japan including medicine, engineering, law, letters, and science. It offers medical services, and diagnoses and treats various health problems in the fields of psychiatry, dermatology, ophthalmology, internal medicine, otolaryngology, and sports orthopedic medicine. Kyoto conducts research programs on fetal brain development in chimpanzees, cerebral development in chimpanzees, and others. The university operates through faculties, graduate schools, research institutes, and research and educational centers. It operates in China, Indonesia, India, Thailand, Singapore, Malaysia, Peru, Ethiopia, Vietnam, the US, the UK, Zambia, Kenya, and other countries. Kyoto is headquartered in Kyoto, Japan.

Kyoto University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kyoto University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kyoto University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kyoto University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kyoto University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Kyoto University, Medical Devices Deals, 2011 to YTD 2017 10
Kyoto University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Kyoto University, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
KinoPharma Raises USD1.3 Million in Financing Round 13
Kyoto University Innovation Capital to Invest in Kyoto drug discovery research institute 14
Stem Cell & Device Laboratory Raises USD1.8 Million in Series A Financing 15
Partnerships 16
Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 16
CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 17
Oncolys BioPharma Enters into Research Agreement with Kyoto University 18
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 19
Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 20
CiRA Enters into Co-Development Agreement with Takeda Pharma 21
Shin Nippon Biomedical Labs Enters Into Research Agreement With Center For iPS Cells Research And Application 22
NanoCarrier Extends Research Agreement With Kyoto University 23
NanoCarrier Enters Into Research Agreement With Kyoto University 24
CiRA Enters Into Co-Development Agreement With Kyoto University And Dainippon Sumitomo 25
Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University 26
Takeda Pharma Enters Into Co-Development Agreement With Kyoto University 27
Licensing Agreements 28
FGH Biotech Enters into Licensing Agreement with Kyoto University and Tokyo University of Agriculture and Technology 28
Kyoto Drug Discovery & Development Enters into Licensing Agreement with Kyoto University 29
Sigma Life Science Enters Into Licensing Agreement With Kyoto University 30
iPierian Enters Into Licensing Agreement With Kyoto University 31
Kyoto University And iPS Academia Enter Into Licensing Agreement With iPierian 32
Kyoto University – Key Competitors 33
Kyoto University – Key Employees 34
Kyoto University – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 37
Government and Public Interest 37
Jul 11, 2017: Accessing DNA in the cell’s powerhouse to treat disease 37
Jul 11, 2017: Killing cancer in the heat of the moment 38
Jun 05, 2017: Kyoto University and Astellas Inaugurate “Alliance Station” with Aim of Realizing Advanced Medical Treatments 39
Jun 03, 2016: Unusual combo reduces health risk from atypical antipsychotic 40
Product News 41
May 06, 2016: Researchers Report Progress as They Develop New Approach to Treating Metastatic Melanoma 41
Other Significant Developments 42
Jan 03, 2017: Japan’s foremost medical institute purchases multiple HoloMonitor instruments 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Kyoto University, Pharmaceuticals & Healthcare, Key Facts 2
Kyoto University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kyoto University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kyoto University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kyoto University, Deals By Therapy Area, 2011 to YTD 2017 9
Kyoto University, Medical Devices Deals, 2011 to YTD 2017 10
Kyoto University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
KinoPharma Raises USD1.3 Million in Financing Round 13
Kyoto University Innovation Capital to Invest in Kyoto drug discovery research institute 14
Stem Cell & Device Laboratory Raises USD1.8 Million in Series A Financing 15
Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 16
CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 17
Oncolys BioPharma Enters into Research Agreement with Kyoto University 18
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 19
Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 20
CiRA Enters into Co-Development Agreement with Takeda Pharma 21
Shin Nippon Biomedical Labs Enters Into Research Agreement With Center For iPS Cells Research And Application 22
NanoCarrier Extends Research Agreement With Kyoto University 23
NanoCarrier Enters Into Research Agreement With Kyoto University 24
CiRA Enters Into Co-Development Agreement With Kyoto University And Dainippon Sumitomo 25
Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University 26
Takeda Pharma Enters Into Co-Development Agreement With Kyoto University 27
FGH Biotech Enters into Licensing Agreement with Kyoto University and Tokyo University of Agriculture and Technology 28
Kyoto Drug Discovery & Development Enters into Licensing Agreement with Kyoto University 29
Sigma Life Science Enters Into Licensing Agreement With Kyoto University 30
iPierian Enters Into Licensing Agreement With Kyoto University 31
Kyoto University And iPS Academia Enter Into Licensing Agreement With iPierian 32
Kyoto University, Key Competitors 33
Kyoto University, Key Employees 34
Kyoto University, Other Locations 35
Kyoto University, Subsidiaries 35

★海外企業調査レポート[Kyoto University-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Autodesk Inc:企業のM&A・事業提携・投資動向
    Autodesk Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Autodesk Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Laboratorio Reig Jofre SA (RJF):製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratorio Reig Jofre SA (Reig Jofre) is a pharmaceutical company that researches, develops, manufactures and markets medicinal products and nutritional supplements. The company’s product categories include specialized technology products, specialty therapeutic areas, and consumer healthcar …
  • GRP Limited (GRPLTD):企業の財務・戦略的SWOT分析
    GRP Limited (GRPLTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Hannover Ruck SE:企業の戦略・SWOT・財務分析
    Hannover Ruck SE - Strategy, SWOT and Corporate Finance Report Summary Hannover Ruck SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Lanco Infratech Ltd (LITL):企業の財務・戦略的SWOT分析
    Lanco Infratech Ltd (LITL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • INFINITT Healthcare Co., Ltd (071200):企業の財務・戦略的SWOT分析
    INFINITT Healthcare Co., Ltd (071200) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • PDL BioPharma Inc (PDLI)-製薬・医療分野:企業M&A・提携分析
    Summary PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions …
  • Saft Groupe SA:企業の戦略的SWOT分析
    Saft Groupe SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Empresaria Group plc (EMR):企業の財務・戦略的SWOT分析
    Empresaria Group plc (EMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Entia Biosciences Inc (ERGO):企業の財務・戦略的SWOT分析
    Summary Entia Biosciences Inc (EBI) is a biotechnology company that provides nutrigenomics solutions for organic health, beauty and agriculture. The company’s solution includes ErgoD2, mushroom dietary supplement, and multi joint support. It offers ErgoD2 solutions such as Ergo-D2-Hemo, Ergo-D2-FLEX …
  • L’Oreal SA:企業の戦略・SWOT・財務情報
    L'Oreal SA - Strategy, SWOT and Corporate Finance Report Summary L'Oreal SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Apetit Oyj:企業の戦略・SWOT・財務情報
    Apetit Oyj - Strategy, SWOT and Corporate Finance Report Summary Apetit Oyj - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Fugro NV (FUR):企業の財務・戦略的SWOT分析
    Fugro NV (FUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Aplus Financial Co Ltd.:企業の戦略・SWOT・財務情報
    Aplus Financial Co Ltd. - Strategy, SWOT and Corporate Finance Report Summary Aplus Financial Co Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Vocalink Limited
    Vocalink Limited - Strategy, SWOT and Corporate Finance Report Summary Vocalink Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Rexel S.A.:戦略・SWOT・企業財務分析
    Rexel S.A. - Strategy, SWOT and Corporate Finance Report Summary Rexel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Relisys Medical Devices Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Relisys Medical Devices Ltd (Relisys), formerly Care Polymed Ltd is a medical device company that develops, manufactures and commercializes catheter products. The company’s products include drug eluting stent systems, bare metal stent systems, PTCA catheters and angiographic catheters. Its a …
  • Companhia Energetica de Minas Gerais – CEMIG:企業のM&A・事業提携・投資動向
    Companhia Energetica de Minas Gerais - CEMIG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Companhia Energetica de Minas Gerais - CEMIG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, d …
  • Edion Corporation (2730):企業の財務・戦略的SWOT分析
    Edion Corporation (2730) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Smiths Group plc:戦略・SWOT・企業財務分析
    Smiths Group plc - Strategy, SWOT and Corporate Finance Report Summary Smiths Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆